The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,813,782 in first-year total cost, median $301,691.
Most frequent study sections
- Special Emphasis Panel[ZTR1 SBIR-3 (01)]2
- Special Emphasis Panel[ZTR1 CI-3 (01)]1
- Special Emphasis Panel[ZTR1 CI-5 (01)]1
- Special Emphasis Panel[ZTR1 CI-8 (02)]1
- Special Emphasis Panel[ZTR1 SBIR-5 (01)]1
Most frequent institutions
- FHC, INC.1
- NANODE THERAPEUTICS, INC.1
- NUBAD, LLC1
- PRECISION VIROLOGICS, INC.1
- RITHIM BIOLOGICS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Developing Nanopieces, a Platform RNAi Delivery Technology for Treatment of Multiple Diseases1R41TR002298-01A1 | CHEN, QIAN | NANODE THERAPEUTICS, INC., RI | $325,000 | ZTR1 |
| 2020 | DEVELOPMENT OF NOVEL AMINOGLYCOSIDE POLYMERS AND NANOPARTICLES FOR NUCLEIC ACID DELIVERY IN CHRONIC WOUNDS1R41TR003247-01 | REGE, KAUSHAL | SYNERGYAN, LLC, AZ | $324,999 | ZTR1 |
| 2020 | Delivery of chemically modified PNA oligomers1R41AI152613-01 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $299,999 | ZTR1 |
| 2019 | Biologically Targeted Vaccine for Chikungunya1R41AI138964-01A1 | STREBLOW, DANIEL N | PRECISION VIROLOGICS, INC., MO | $300,000 | ZTR1 |
| 2018 | Optimizing Direct Delivery of Nucleic Acid Therapeutics1R41MH119804-01 | RANA, KULDEEPSINH | FHC, INC., ME | $303,381 | ZTR1 |
| 2018 | Catheter Development for Epicardial Atrial Gene Painting1R41TR002425-01 | DONAHUE, J KEVIN | RITHIM BIOLOGICS, INC., MD | $260,403 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.